Bioamber Inc (NYSE:BIOA) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 4,811,928 shares, an increase of 111.4% from the October 13th total of 2,276,412 shares. Based on an average daily volume of 3,835,155 shares, the days-to-cover ratio is presently 1.3 days. Currently, 11.3% of the shares of the company are sold short.
A number of research analysts have recently weighed in on BIOA shares. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Bioamber in a research report on Wednesday, November 8th. Cowen reissued a “hold” rating and issued a $1.00 price objective on shares of Bioamber in a research note on Friday, November 10th. Finally, ValuEngine downgraded shares of Bioamber from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $6.50.
Several institutional investors have recently bought and sold shares of BIOA. Bank of New York Mellon Corp lifted its holdings in Bioamber by 336.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock worth $139,000 after buying an additional 41,701 shares in the last quarter. FMR LLC lifted its holdings in Bioamber by 18.7% during the 1st quarter. FMR LLC now owns 1,335,000 shares of the biotechnology company’s stock worth $3,097,000 after buying an additional 210,000 shares in the last quarter. Robecosam AG lifted its holdings in Bioamber by 82.9% during the 3rd quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock worth $741,000 after buying an additional 670,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Bioamber by 9.9% during the 2nd quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock worth $780,000 after buying an additional 27,278 shares in the last quarter. Finally, TD Asset Management Inc. acquired a new stake in shares of Bioamber in the 2nd quarter valued at $977,000. 29.97% of the stock is owned by institutional investors and hedge funds.
Shares of Bioamber (BIOA) remained flat at $$0.42 during midday trading on Monday. 665,042 shares of the stock were exchanged, compared to its average volume of 947,172. Bioamber has a fifty-two week low of $0.32 and a fifty-two week high of $6.24. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.75 and a current ratio of 1.08.
ILLEGAL ACTIVITY NOTICE: “Bioamber Inc (NYSE:BIOA) Short Interest Up 111.4% in October” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/04/short-interest-in-bioamber-inc-bioa-increases-by-111-4.html.
Bioamber Company Profile
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
Receive News & Ratings for Bioamber Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber Inc and related companies with MarketBeat.com's FREE daily email newsletter.